Annual EBITDA
-$495.21 M
+$122.18 M+19.79%
31 December 2023
Summary:
Apellis Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$495.21 million, with the most recent change of +$122.18 million (+19.79%) on 31 December 2023. During the last 3 years, it has fallen by -$182.98 million (-58.60%). APLS annual EBITDA is now -12208.58% below its all-time high of -$4.02 million, reached on 31 December 2013.APLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$43.70 M
-$15.91 M-57.25%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$43.70 million, with the most recent change of -$15.91 million (-57.25%) on 30 September 2024. Over the past year, it has increased by +$88.59 million (+66.97%). APLS quarterly EBITDA is now -148.56% below its all-time high of $90.00 million, reached on 31 December 2020.APLS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$209.71 M
+$88.59 M+29.70%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$209.71 million, with the most recent change of +$88.59 million (+29.70%) on 30 September 2024. Over the past year, it has increased by +$365.54 million (+63.54%). APLS TTM EBITDA is now -7763.10% below its all-time high of -$2.67 million, reached on 30 September 2014.APLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.8% | +67.0% | +63.5% |
| 3 y3 years | -58.6% | +77.4% | +57.8% |
| 5 y5 years | -296.2% | +36.7% | +7.0% |
APLS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -58.6% | +32.3% | -57.3% | +77.4% | at high | +71.3% |
| 5 y | 5 years | -296.2% | +32.3% | -148.6% | +79.7% | at high | +71.3% |
| alltime | all time | <-9999.0% | +32.3% | -148.6% | +79.7% | -7763.1% | +71.3% |
Apellis Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$43.70 M(+57.3%) | -$209.71 M(-29.7%) |
| June 2024 | - | -$27.79 M(-52.9%) | -$298.30 M(-22.4%) |
| Mar 2024 | - | -$58.96 M(-25.6%) | -$384.60 M(-22.3%) |
| Dec 2023 | -$495.21 M(-19.8%) | -$79.26 M(-40.1%) | -$495.21 M(-13.9%) |
| Sept 2023 | - | -$132.29 M(+15.9%) | -$575.25 M(-8.0%) |
| June 2023 | - | -$114.09 M(-32.7%) | -$625.52 M(-5.0%) |
| Mar 2023 | - | -$169.57 M(+6.4%) | -$658.13 M(+6.6%) |
| Dec 2022 | -$617.39 M(-15.6%) | -$159.30 M(-12.7%) | -$617.39 M(+2.5%) |
| Sept 2022 | - | -$182.56 M(+24.4%) | -$602.28 M(-1.7%) |
| June 2022 | - | -$146.70 M(+13.9%) | -$612.73 M(-10.0%) |
| Mar 2022 | - | -$128.83 M(-10.7%) | -$681.01 M(-6.9%) |
| Dec 2021 | -$731.27 M(+134.2%) | -$144.19 M(-25.3%) | -$731.27 M(+47.1%) |
| Sept 2021 | - | -$193.01 M(-10.2%) | -$497.08 M(+15.6%) |
| June 2021 | - | -$214.98 M(+20.0%) | -$429.95 M(+31.7%) |
| Mar 2021 | - | -$179.09 M(-299.0%) | -$326.56 M(+4.6%) |
| Dec 2020 | -$312.23 M(+4.5%) | $90.00 M(-171.5%) | -$312.23 M(-38.9%) |
| Sept 2020 | - | -$125.89 M(+12.8%) | -$511.30 M(+12.5%) |
| June 2020 | - | -$111.59 M(-32.3%) | -$454.50 M(+9.9%) |
| Mar 2020 | - | -$164.76 M(+51.1%) | -$413.72 M(+38.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$298.83 M(+139.1%) | -$109.07 M(+57.9%) | -$298.83 M(+32.6%) |
| Sept 2019 | - | -$69.08 M(-2.4%) | -$225.40 M(+17.8%) |
| June 2019 | - | -$70.81 M(+42.0%) | -$191.29 M(+24.9%) |
| Mar 2019 | - | -$49.87 M(+39.9%) | -$153.21 M(+23.1%) |
| Dec 2018 | -$124.99 M(+146.9%) | -$35.64 M(+1.9%) | -$124.41 M(+16.7%) |
| Sept 2018 | - | -$34.97 M(+6.8%) | -$106.63 M(+28.1%) |
| June 2018 | - | -$32.73 M(+55.3%) | -$83.25 M(+32.9%) |
| Mar 2018 | - | -$21.07 M(+18.0%) | -$62.65 M(+23.7%) |
| Dec 2017 | -$50.63 M(+86.7%) | -$17.86 M(+54.1%) | -$50.63 M(+28.8%) |
| Sept 2017 | - | -$11.59 M(-4.5%) | -$39.30 M(+12.5%) |
| June 2017 | - | -$12.13 M(+34.0%) | -$34.94 M(+53.2%) |
| Mar 2017 | - | -$9.05 M(+38.8%) | -$22.81 M(+65.8%) |
| Dec 2016 | -$27.12 M(+35.0%) | -$6.52 M(-9.9%) | -$13.76 M(-3.1%) |
| Sept 2016 | - | -$7.23 M(+3.9%) | -$14.20 M(+17.1%) |
| Dec 2015 | -$20.09 M(+78.0%) | -$6.96 M(+35.0%) | -$12.12 M(+50.2%) |
| Sept 2015 | - | -$5.16 M(+77.0%) | -$8.07 M(+44.6%) |
| Dec 2014 | -$11.29 M(+180.6%) | -$2.91 M(+9.3%) | -$5.58 M(+109.3%) |
| Sept 2014 | - | -$2.67 M | -$2.67 M |
| Dec 2013 | -$4.02 M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual EBITDA year-on-year change?
- What is Apellis Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Apellis Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM EBITDA year-on-year change?
What is Apellis Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of APLS is -$495.21 M
What is the all time high annual EBITDA for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.02 M
What is Apellis Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, APLS annual earnings before interest, taxes, depreciation & amortization has changed by +$122.18 M (+19.79%)
What is Apellis Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of APLS is -$43.70 M
What is the all time high quarterly EBITDA for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $90.00 M
What is Apellis Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, APLS quarterly earnings before interest, taxes, depreciation & amortization has changed by +$88.59 M (+66.97%)
What is Apellis Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of APLS is -$209.71 M
What is the all time high TTM EBITDA for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.67 M
What is Apellis Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, APLS TTM earnings before interest, taxes, depreciation & amortization has changed by +$365.54 M (+63.54%)